StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV - Free Report) in a research note published on Saturday. The firm issued a hold rating on the biopharmaceutical company's stock.
Separately, D. Boral Capital initiated coverage on MediciNova in a research report on Monday, December 2nd. They set a "buy" rating and a $9.00 price objective for the company.
Check Out Our Latest Report on MNOV
MediciNova Stock Performance
Shares of NASDAQ MNOV traded down $0.04 during trading on Friday, hitting $1.83. 24,902 shares of the company were exchanged, compared to its average volume of 33,330. MediciNova has a 12-month low of $1.12 and a 12-month high of $2.55. The company has a fifty day moving average price of $2.06 and a 200-day moving average price of $1.74. The firm has a market capitalization of $89.76 million, a PE ratio of -8.71 and a beta of 0.84.
Institutional Investors Weigh In On MediciNova
A hedge fund recently bought a new stake in MediciNova stock. Jane Street Group LLC bought a new stake in MediciNova, Inc. (NASDAQ:MNOV - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 14,138 shares of the biopharmaceutical company's stock, valued at approximately $30,000. Institutional investors own 9.90% of the company's stock.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
